You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer

Authors

  • Qiangda Chen Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Hanlin Yin Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Zhenlai Jiang Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Taochen He Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Yuqi Xie Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Weilin Mao Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Jiande Han Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Siyao Liu Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Wenhui Lou Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Wenchuan Wu Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Joseph R Habib Department of Surgery, New York University School of Medicine and NYU Langone Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Jun Yu Departments of Medicine, Oncology and Surgery, Johns Hopkins University, Baltimore, Maryland, USA Pancreas Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China PubMed articlesGoogle scholar articles
  • Liang Liu Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Ning Pu Department of Pancreatic Surgery, Zhongshan Hospital Fudan University, Shanghai, China Cancer Center, Zhongshan Hospital Fudan University, Shanghai, China PubMed articlesGoogle scholar articles

Citation

Chen Q, Yin H, Jiang Z, et al
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer
Journal for ImmunoTherapy of Cancer 2024;12:e008694. doi: 10.1136/jitc-2023-008694
Online issue publication 
March 26, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.